Liquidia

LQDA on Nasdaq. Liquidia sells inhaled and injectable lung-disease drugs to U.S. doctors and patients. Market value $5.2bn.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

We can't read total debt from the filing, so debt is left out.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
5.9%fair

For every $100 of what the whole company costs, it produced $5.94 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
n/a

The filings do not give us enough to work this out.

Quality score: 40 of 100. Price score: 32 of 100. Our list needs 70 on quality and 60 on price.

$54.43 a share, 144% above its 1-year low

Over the past year the price has ranged from $22.31 to $93.61.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.0
-0.0
-0.0
-0.1
-0.0
0.3
2021202220232024202512 monthsto Sep '26

Spare cash swings from quarter to quarter here: $291 million in the past 12 months, a shortfall of $40 million in the year to December 2025.

Revenue
$13m$16m$17m$14m$158m
Operating margin
-263.0%-243.3%-419.6%-866.6%-32.5%
Debt to equity
0.170.22n/an/an/a
Shares outstanding
0.06bn0.06bn0.08bn0.09bn0.09bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)2 of 7 checks we could run
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsStrong, 192.5% a year
  • Buying back its own sharesNo, 40% more shares since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • Sales: $225 million last quarter, up 315% on a year ago.
  • A loss of $236 million, compared with a loss of $4 million a year ago.
  • It loses 16 cents on each $1 of sales, compared with 155 cents a year earlier.
  • Spare cash over the past 12 months: $291 million. A year earlier it spent $104 million more than it brought in.
  • 4% more shares than a year ago. Each share owns a bit less of the company.
  • Sales grew on a year ago in each of the last 4 quarters.
Sales by quarter
Sales by quarter
Quarter toAmount
December 2024$3m
March 2025$3m
June 2025$9m
September 2025$54m
December 2025$92m
March 2026$133m
June 2026$172m
September 2026$225m
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$39m
March 2025-$38m
June 2025-$42m
September 2025-$4m
December 2025Not reported
March 2026$53m
June 2026$75m
September 2026-$236m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
5 March 2026
Next quarterly (estimated, 10-Q)
9 February 2027

Who owns it

2 long-term investors we follow own it, up from 1 last quarter. 336 funds in all.

Jun '25
Dec '25
Jun '26
Largest holders overall

From 13F filings for the quarter ended 30 June 2026.

Big holders and activists

4 investors own more than 5%.

  • BlackRock, Inc.
    Passive investor
    11.9%
    Since 30 June 2026
  • at least 9.4%−0.5 pts
    (filed with 28 related holders)
    Since 30 June 2026
  • Paul B Manning
    Passive investor
    at least 6.5%
    (filed with 2 related holders)
    Since 30 June 2026
  • IsZo Capital LP
    Passive investor
    at least 5.2%
    (filed with 3 related holders)
    Since 12 November 2026
  • Legend Aggregator, LP
    Passive investor
    Sold down below 5%
    Since 31 December 2024
  • Farallon Capital Partners, L.P.
    Passive investor
    Sold down below 5%
    Since 31 December 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

In the last 12 months, 1 insider bought $317,894 of shares on the open market. 15 sold $227m, $75m of it under preset trading plans.

  • Boyle Dana
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    26 October 2026
    Shares
    1,581
    Price
    $43.19
    Value
    $68,283
  • Adair Jason
    Chief Business Officer
    Sold
    under a preset trading plan
    Date
    26 October 2026
    Shares
    688
    Price
    $43.19
    Value
    $29,715
  • Schundler Russell
    General Counsel
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    13,692
    Price
    $28.48
    Value
    $389,948
  • Saggar Rajeev
    Chief Medical Officer
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    9,218
    Price
    $28.48
    Value
    $262,529
  • Moomaw Scott
    Chief Commercial Officer
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    8,863
    Price
    $28.48
    Value
    $252,418
  • Krepp Sarah
    Chief Human Resource Officer
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    5,245
    Price
    $28.48
    Value
    $149,378
  • Khindri Sanjeev
    Chief Development Officer
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    1,101
    Price
    $28.48
    Value
    $31,356
  • Kaseta Michael
    CFO and COO
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    18,938
    Price
    $28.48
    Value
    $539,354
  • JEFFS ROGER
    Chief Executive Officer, Director
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    32,744
    Price
    $28.48
    Value
    $932,549
  • Boyle Dana
    Chief Accounting Officer
    Sold
    under a preset trading plan
    Date
    12 October 2026
    Shares
    5,892
    Price
    $28.48
    Value
    $167,804

From Form 4 filings: insiders must report trades in their own company's shares within two days.

Warning signs in its filings

Problems the company itself reported to the SEC, in its own words.

None of the warning signs we check for were found.

We look for five warning signs: doubt it can keep going, weak checks on its own accounts, a notice that its past accounts can't be relied on, a change of auditor, and one customer bringing in a big share of sales. We don't check lawsuits, investigations or debt yet.

We checked the auditor's report, internal controls, restatement notices, auditor changes and big customers in the 10-K filed 5 Mar 2026, plus the 10-Q filed 10 Nov 2026 and 8 later 8-Ks.

A 10-K is the yearly report every US company files with the SEC. An 8-K is a short notice of a big event.

What could go wrong

Cheap for a reason is the question the numbers cannot answer.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.